Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 2/20 | 0.39 |
| ▸ | DRD3 | P35462 | 6/20 | 0.38 |
| ▸ | DRD2 | P14416 | 5/20 | 0.38 |
| ▸ | DRD4 | P21917 | 5/20 | 0.38 |
| ▸ | DRD1 | P21728 | 3/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | DRD5 | P21918 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | NOS3 | P29474 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24960728 | 0.80 | CHRM2 (0.49) | HDAC1HDAC6ALDH1A1GAAKMT2A | |
| SCHEMBL24960646 | 0.77 | ALDH1A1 (0.44) | DRD2DRD4ALDH1A1KMT2ALMNA | |
| SCHEMBL15037993 | 0.76 | HRH3 (0.43) | RENDRD3DRD2DRD4HRH3 | |
| Hydrochloric Acid SCHEMBL15016566 | 0.75 | KMT2A (0.44) | RENDRD3DRD2HRH3HTR1A | |
| SCHEMBL24960658 | 0.74 | MAP4K1 (0.45) | — | |
| SCHEMBL21468535 | 0.74 | S100B (0.38) | DRD3DRD2DRD4DRD1HDAC1 | |
| SCHEMBL27580531 | 0.74 | POLB (0.37) | HDAC1HDAC6ALDH1A1GAA | |
| SCHEMBL10092657 | 0.71 | MEN1 (0.47) | RENDRD3DRD2DRD4DRD1 | |
| SCHEMBL20232219 | 0.71 | MAOB (0.63) | DRD3DRD2DRD4DRD1DRD5 | |
| SCHEMBL20214396 | 0.71 | MAOB (0.63) | DRD3DRD2DRD4DRD1DRD5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230026840-A1 | COMPOUND USED AS EGFR KINASE INHIBITOR AND USE THEREOF | TYK MEDICINES, INC. (CN) | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230026840-A1 | COMPOUND USED AS EGFR KINASE INHIBITOR AND USE THEREOF | EGFR, ERBB2, ERBB4 | REN 1339/4885DRD3 4825/4885DRD2 4796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.